(202) 599-8435

Third Party Opinion

Instead of Taking Pain Medications Away from Patients, Consider These Options

Proposals to address the drug overdose epidemic often entail removing opioid pain relievers from the market, which would devastate the lives of patients who need them. Alternative solutions that...
Posted on Oct 09, 2017
, By

Natural Disasters Endanger Patients on Life-Sustaining Medications

Hurricanes and other natural disasters pose a significant threat to individuals with chronic illnesses who heavily rely on life-sustaining medications. For example, people with pain are going...
Posted on Sep 13, 2017
, By

WSJ: Governments Exploit Overdose Epidemic To Pad Their Budgets

The editorial board of The Wall Street Journal writes that state and local governments suing prescription opioid manufacturers have so far failed to show that the defendants’ alleged...
Posted on Aug 01, 2017
, By

Person with Pain Shares View from Other Side of Opioid Overdose Epidemic

A person with persistent pain offers a different perspective on the opioid overdose epidemic, explaining how it affects individuals who rely on pain medicine to function daily. While much needed...
Posted on Jul 28, 2017
, By

Opioid Overdose Epidemic Is Not Unprecedented

Nearly 150 years ago, the United States faced a similar opioid-related epidemic when doctors began injecting morphine to treat even the slightest complaint of pain. The change in how doctors...
Posted on Jul 24, 2017
, By

Sales of Naltrexone Skyrocket with Little Evidence To Support Its Use

Not a single published trial has compared long-acting naltrexone to methadone or buprenorphine for the treatment of opioid use disorder. Long-acting naltrexone’s appeal is largely its physical...
Posted on Jul 13, 2017
, By

Barthwell: Science, Not Stigma, Must Underlie Policy

In this KevinMD op-ed, Dr. Andrea Barthwell, CLAAD co-founder and CEO of Two Dreams, along with Dr. Genie Bailey, ASAM physician, urges policy makers to look to science, not stigma, in addressing...
Posted on Jun 08, 2017
, By

Mandating ADFs for Canadian Prescription Opioids Could Reduce Societal Costs

The Canadian Health Policy Institute (CHPI) has published a study which estimates that if all prescription opioids in Canada were abuse deterrent formulations (ADFs), societal costs in the form...
Posted on May 30, 2017
, By

New Report Would Perpetuate the Opioid Overdose Epidemic

A new report by the Institute for Clinical and Economic Review (ICER) incorrectly claims that abuse-deterrent opioids provide neither financial nor societal benefits. The report focuses on how...
Posted on May 15, 2017
, By